Dual-listed cancer diagnostics company Pacific Edge is assessing the implications of Novitas’s decision its Cxbladder tests will not be covered by US national health insurance provider Medicare and expects to provide a full update before trading opens on Wednesday morning.
And analysts are now
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
